SANOFI-ADR (SNY)

US80105N1054 - ADR

52.4  -0.7 (-1.32%)

After market: 52.4 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SANOFI-ADR

NASDAQ:SNY (7/26/2024, 7:00:02 PM)

After market: 52.4 0 (0%)

52.4

-0.7 (-1.32%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month4.51%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap131.11B
Shares
PE14.12
Fwd PE11.01
Dividend Yield4.02%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SNY Daily chart

Company Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 87,994 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

Company Info

SANOFI-ADR

46 Avenue de la Grande Armee

Paris ILE-DE-FRANCE 75008

P: 33153774000

CEO: Paul Hudson

Employees: 87994

Website: https://www.sanofi.com/

SNY News

News Imagea day ago - The Motley FoolSanofi (SNY) Q2 2024 Earnings Call Transcript

SNY earnings call for the period ending June 30, 2024.

News Image2 days ago - The Motley Fool25 Best Artificial Intelligence Stocks to Buy Right Now

Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.

News Image9 days ago - Swedish Orphan Biovitrum ABNEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

/PRNewswire/ -- Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM)...

News Image10 days ago - InvestorPlaceStable Blue-Chip Stocks to Buy Before Earnings Season

Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth.

News Image16 days ago - SanofiSanofi ships U.S. influenza vaccines for the 2024/25 season

/PRNewswire/ -- Sanofi today started shipping its first influenza (flu) vaccines across the U.S. in preparation for the 2024/25 flu season. Following this...

News Image17 days ago - InvestorPlace3 Stocks to Sell Immediately Based on the French Election Results

Discover why Engie S.A., Sanofi, and Carrefour are prime candidates for divestment post-French elections amid potential policy impacts.

SNY Twits

Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example